Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q1 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Company News for May 3, 2021

by Zacks Equity Research

Companies In The News Are: AON, ALXN, CLX, QSR.

Alexion Pharmaceuticals (ALXN) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Alexion (ALXN) delivered earnings and revenue surprises of 14.29% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track

by Zacks Equity Research

Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.

AstraZeneca (AZN) Q1 Earnings Top, COVID-19 Vaccine Adds $275M

by Zacks Equity Research

AstraZeneca (AZN) surpasses first-quarter estimates on both counts. Stock up in pre-market.

Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus

by Zacks Equity Research

Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.

Analysts Estimate Alexion Pharmaceuticals (ALXN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.

Alexion Pharmaceuticals (ALXN) is Overbought: Is A Drop Coming?

by Zacks Equity Research

Alexion Pharmaceuticals (ALXN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.

Alexion (ALXN) Moves 3.9% Higher: Will This Strength Last?

by Zacks Equity Research

Alexion (ALXN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Immunovant (IMVT) Gains on a Potential Buyout by Roivant

by Zacks Equity Research

Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.

Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report?

by Zacks Equity Research

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus

by Zacks Equity Research

Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.

Sanghamitra Saha headshot

Nasdaq ETF's Worst Day Since October: Stocks That Survived

by Sanghamitra Saha

The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.

Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals

by Zacks Equity Research

Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals

Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.

Sumit Singh headshot

Pick These 4 Low P/CF Stocks for a Value-Based Portfolio

by Sumit Singh

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuticals (ALXN) boast low P/CF ratio.

Gilead (GILD) & Galapagos Discontinue Development of IPF Drug

by Zacks Equity Research

Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.

ALXN vs. BMRN: Which Stock Is the Better Value Option?

by Zacks Equity Research

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

5 Best PEG-Driven Value Stocks Amid COVID-Led Uncertainty

by Urmimala Biswas

Here are five of the 61 value stocks with discounted PEG.

AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes

by Zacks Equity Research

AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.

Palatin (PTN) Jumps: Stock Rises 8.7%

by Zacks Equity Research

Palatin (PTN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.